Medicus Pharma (MDCX) Company Report

Medicus Pharma Ltd. will ring the Nasdaq Opening Bell on Thursday, January 22, 2026, to commemorate its one-year anniversary as a Nasdaq-listed company.
The company's pipeline includes , a therapy for basal cell carcinoma with an estimated $2 billion market opportunity, and , targeting advanced prostate cancer with an estimated $6 billion opportunity.
Medicus completed enrollment of 90 patients in the U.S. for the SkinJect Phase 2 clinical study (SKNJCT-003) in December 2025 and expects to release topline results in Q1 2026.
Recent strategic developments include the acquisition of Antev in August 2025, which added Teverelix to its pipeline, and a non-binding letter of intent in December 2025 with Reliant AI Inc. for an AI-driven clinical data analytics platform.

Jan 20, 2026, 12:30 PM

Medicus Pharma Reports Positive Phase 1 Teverelix Data and Upcoming AACE Presentation

MDCX

New Projects/Investments

Product Launch

Medicus Pharma Ltd. announced that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, scheduled for April 22–24 in Las Vegas, Nevada.
Phase 1 studies involving 48 healthy premenopausal women demonstrated rapid, reversible hormone suppression (LH, FSH, and estradiol) within 24 hours of dosing, with sustained activity for up to two to three weeks at higher doses.
Key findings also include stable bone turnover markers, suggesting no evidence of short-term bone loss, and a favorable safety profile with only mild-to-moderate treatment-emergent adverse events.
These results support the advancement of Teverelix into women's health indications, such as endometriosis, with regulatory planning underway for a Phase 2 study in the United Arab Emirates (UAE).
In parallel, Medicus is advancing SkinJect™ for basal cell carcinoma, having completed Phase 2 enrollment, with topline decision-grade data expected in Q1 2026.

Jan 12, 2026, 12:30 PM

Medicus Pharma Ltd. to Present at Biotech Showcase 2026; SkinJect Phase 2 Data Readout Expected in Q1 2026

MDCX

New Projects/Investments

Medicus Pharma Ltd. will present at Biotech Showcase 2026 on January 13, 2026, to discuss multiple Phase 2 catalysts across its clinical, regulatory, and pipeline expansion programs.
The company completed enrollment of 90 patients in its SkinJect™ Phase 2 study (SKNJCT-003) in December 2025 and expects to report topline results in the first quarter of 2026.
Medicus acquired Antev Limited in August 2025, adding Teverelix, a GnRH antagonist for advanced prostate cancer, to its pipeline.
In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc. for an AI-driven clinical data analytics platform, with initial support for a Teverelix clinical study planned for 2026.

Jan 5, 2026, 12:30 PM

Medicus Pharma Ltd. Enters Warrant Inducement Agreement

MDCX

Medicus Pharma Ltd. entered into a warrant inducement agreement on December 5, 2025, with an accredited and institutional holder.
The agreement facilitates the immediate exercise of existing Series A and Series B Warrants to purchase 2,680,000 common shares at an amended exercise price of $1.92 per share.
This exercise is expected to generate approximately $5.1 million in gross proceeds for the company.
In consideration for the exercise of existing warrants, Medicus Pharma Ltd. will issue new unregistered Series C and Series D Warrants to purchase up to 4,020,000 common shares with an exercise price of $2.00 per share.

Dec 8, 2025, 9:30 PM

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer

MDCX

CFO Change

Management Change

Executive Compensation

Medicus Pharma Ltd. has appointed Carolyn Bonner as its Chief Financial Officer, effective December 1, 2025. She will also continue to serve as the company's President, a role she has held since September 2023.
Ms. Bonner had been serving as Acting Chief Financial Officer since September 12, 2025, and succeeds James Quinlan, who formally resigned for health reasons on November 28, 2025.
In her combined role, Ms. Bonner will receive an annual base salary of $395,000 and is eligible for an annual discretionary bonus plan, starting at 60% of her base salary in the first year and increasing to 100% by the fifth year.
The company also provided updates on its clinical development programs, including the SKNJCT-003 Phase 2 clinical study and the SKNJCT-004 study in the UAE, as well as the acquisition of Antev Limited in August 2025.

Dec 1, 2025, 1:13 PM

Medicus Pharma Ltd. Reports Q3 2025 Financial Highlights and Corporate Updates

MDCX

Earnings

M&A

New Projects/Investments

Medicus Pharma Ltd. reported a net loss of $16.0 million for Q3 2025, significantly higher than the $2.3 million net loss in Q3 2024, with total operating expenses rising to $15.4 million from $2.3 million.
The company's cash and cash equivalents increased to $8.7 million by the end of Q3 2025, compared to $5.3 million in Q3 2024, supported by $10.4 million in net proceeds from financing and warrant exercises.
In August 2025, Medicus completed the acquisition of Antev Limited, integrating Teverelix, a next-generation GnRH antagonist for advanced prostate cancer and acute urinary retention, into its drug development pipeline.
The SkinJect clinical development program is progressing, with the Phase 2 SKNJCT-003 study having randomized over 75% of participants by August 2025 and expanding to the UK in November 2025, and the SKNJCT-004 study initiating patient treatment in the UAE in October 2025.

Nov 14, 2025, 10:17 PM

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

MDCX

Debt Issuance

New Projects/Investments

Medicus Pharma Ltd. secured an $8.0 million non-dilutive debenture financing from YA II PL, Ltd. (Yorkville) on September 17, 2025.
The debenture carries an annual interest rate of 8% and has a maturity date of September 17, 2026.
After refinancing an existing $1.7 million debenture, original issue discount, and fees, the net proceeds to the company are approximately $5.7 million.
The company plans to use the proceeds to accelerate the development of Teverelix for Acute Urinary Retention and high CV risk Prostate Cancer, targeting a potential market opportunity of ~$6 billion.

Sep 18, 2025, 12:00 PM

Get instant answers from SEC filings, earnings calls & more